Explore 3 Stock Ideas & Industry Insights Download Free Report

888-969-2592
Shopping Cart 0
countryflagCA
Login

Home CompaniesEastwood Bio-Medical Canada Inc

Eastwood Bio-Medical Canada Inc

Consumer Defensive Food Distribution
PortfolioPortfolio WatchlistWatchlist
Company price
1.89 CAD -0.04 ( 2.07%)
Last update at 2026-11-04T20:45:00Z
VOLUME
1651
Market Cap
47.53M

Momentum Score

…

Eastwood Bio-Medical Canada Inc. markets, develops research, and distributes natural health products under the Eleotin brand in Canada, the United States, and Asia. The company distributes Eleotin, which provides natural remedies for metabolic disorders, such as blood glucose disorders, hypertension, and obesity. It also offers Eleotin A 700 for the treatment for spleen deficiency, lack of appetite, and fatigue; Eleotin AL88 for laxative; Eleotin Cal20 for bone and teeth maintenance; Eleotin V3D for bones, teeth, and health; Eleotin G2000 for cardiovascular health; Eleotin H55 for sedative and tension relief; and Eleotin Zn330 for tissue formation and metabolism. In addition, the company provides Eleotin Bentley to promote healthy glucose levels; and Eleotin LBM for hypertension relief. The company was incorporated in 2010 and is based in Richmond, Canada. Eastwood Bio-Medical Canada Inc. is a subsidiary of Eastwood Bio-Medical Research Inc.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
1.80
Low
1.89
High
52 Week Price Range
0.29
Low
1.10
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High
AI Summary

Eastwood Bio-Medical Canada Inc is a small Canada-based company listed on the TSX Venture Exchange (ticker EBM.V) with limited public disclosures about its operations. Long-term growth prospects appear to depend on clinical development, regulatory approvals and successful commercialization of any biomedical technologies it may develop, which could be supported by partnerships or capital raises.
Material risks include scarce public information, early-stage development, need for additional financing, regulatory and commercialization uncertainty, and low liquidity in the stock.

Risk Score
High

Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.

Key Metrics*

Previous Close
1.93
Dividend Yield
-
Revenue TTM
0.72M
Revenue Per Share
0.01
Gross Profit TTM
0.50M
Debt / Equity
-0.03
ROE
-747.16%
Net Debt
0.06M
ROCE
17.94%
Diluted EPS TTM
-0.01

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-10-31 2024-10-31 2023-10-31 2022-10-31 2021-10-31
Type yearly yearly yearly yearly yearly
Date 2025-10-31 2024-10-31 2023-10-31 2022-10-31 2021-10-31
Income before tax -0.33M -0.46M -0.55M -0.15M -0.60M
Net income -0.33M -0.46M -0.55M -0.15M -0.60M
Selling general administrative 0.61M 0.53M 0.67M 0.93M 0.97M
Selling and marketing expenses - - 0.00M - -
Gross profit 0.55M 0.45M 0.44M 0.90M 0.46M
Reconciled depreciation 0.04M 0.11M 0.11M 0.11M 0.11M
Ebit - - -0.51M -0.11M -0.57M
Ebitda - - -0.40M -0.03M -0.49M
Depreciation and amortization - - 0.11M - -
Operating income -0.29M -0.44M -0.51M -0.13M -0.60M
Other operating expenses - - 1.37M - -
Interest expense - 0.01M 0.03M 0.01M 0.00M
Interest income - - - - 0.00M
Net interest income -0.01M -0.01M -0.03M -0.01M -0.00M
Income tax expense - - -0.00M - -
Total revenue 0.78M 0.70M 0.87M 1.30M 0.98M
Total operating expenses 1.07M 1.14M 0.95M 1.43M 1.58M
Cost of revenue 0.23M 0.25M 0.43M 0.40M 0.52M
Total other income expense net -0.03M -0.01M -0.04M -0.01M -0.00M
Net income from continuing ops -0.33M -0.46M -0.55M -0.15M -0.60M
Net income applicable to common shares - - - -0.15M -0.60M
Breakdown 2025-10-31 2024-10-31 2023-10-31 2022-10-31 2021-10-31
Type yearly yearly yearly yearly yearly
Date 2025-10-31 2024-10-31 2023-10-31 2022-10-31 2021-10-31
Total assets 0.22M 0.27M 0.49M 0.58M 0.69M
Other current assets - - 0.05M - -
Total liab 1.85M 1.57M 1.33M 0.88M 0.84M
Total stockholder equity -1.63M -1.30M -0.84M -0.29M -0.14M
Other current liab - - 1.13M 0.04M 0.10M
Common stock - - 4.69M 4.69M 4.69M
Capital stock 4.69M 4.69M 4.69M 4.69M 4.69M
Retained earnings -6.33M -5.99M -5.54M -4.99M -4.84M
Other assets - - - 0.04M 0.08M
Cash 0.02M 0.00M 0.02M 0.04M 0.02M
Total current liabilities 1.85M 1.57M 1.33M 0.84M 0.80M
Current deferred revenue - - 0.07M - -
Net debt 0.06M 0.08M 0.00M 0.02M 0.01M
Short term debt - - 0.02M - -
Short long term debt 0.08M 0.08M 0.06M 0.03M -
Short long term debt total - - 0.02M - -
Other stockholder equity - - - 0.01M 0.01M
Property plant equipment - - - 0.45M 0.55M
Total current assets 0.03M 0.04M 0.15M 0.10M 0.06M
Net tangible assets - - - -0.29M -0.14M
Net receivables 0.01M 0.04M 0.08M 0.01M 0.01M
Long term debt - - - 0.03M 0.03M
Accounts payable 0.08M 0.08M 0.10M 0.78M 0.71M
Accumulated other comprehensive income - - 0.01M - -
Non current assets total 0.19M 0.23M 0.34M 0.48M 0.63M
Breakdown 2025-10-31 2024-10-31 2023-10-31 2022-10-31 2021-10-31
Type yearly yearly yearly yearly yearly
Date 2025-10-31 2024-10-31 2023-10-31 2022-10-31 2021-10-31
Investments - - 0.00M -0.00M -0.01M
Change to liabilities - - - 0.01M 0.01M
Total cashflows from investing activities - - - -0.00M -0.01M
Net borrowings -0.00M -0.00M -0.00M 0.03M 0.02M
Total cash from financing activities -0.00M -0.00M -0.00M 0.03M 0.02M
Change to operating activities - - - 0.03M 0.38M
Net income -0.33M -0.46M -0.55M -0.15M -0.60M
Change in cash 0.02M -0.02M -0.02M 0.02M -0.10M
Begin period cash flow -0.00M 0.02M 0.04M 0.02M 0.12M
End period cash flow 0.02M -0.00M 0.02M 0.04M 0.02M
Total cash from operating activities 0.02M -0.02M -0.02M -0.00M -0.12M
Depreciation 0.04M 0.11M 0.11M 0.11M 0.11M
Change to account receivables - - 0.00M -0.01M 0.00M
Change to netincome - - - 0.00M -0.01M
Capital expenditures 0.00M 0.00M 0.00M 0.00M 0.01M
Change in working capital 0.29M 0.31M 0.42M 0.03M 0.39M
Other non cash items 0.02M 0.02M 0.00M 0.00M -0.01M
Free cash flow 0.02M -0.02M -0.02M -0.01M -0.12M

Peer Comparison*

Sector: Consumer Defensive Industry: Food Distribution

Stock Name
Change
(CAD)
Price
(CAD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
Enterprise Value
to EBITDA (x)
EBM
Eastwood Bio-Medical Canada Inc		 -0.04
2.07%		 1.89 - - 66.05 2961.32 58.48 34987.50
OGO
Organto Foods Incorporated		 -
-%		 0.34 - - 2.77 16.58 2.60 -5.73

Profile*

Eastwood Bio-Medical Canada Inc

Eastwood Bio-Medical Canada Inc. markets, develops research, and distributes natural health products under the Eleotin brand in Canada, the United States, and Asia. The company distributes Eleotin, which provides natural remedies for metabolic disorders, such as blood glucose disorders, hypertension, and obesity. It also offers Eleotin A 700 for the treatment for spleen deficiency, lack of appetite, and fatigue; Eleotin AL88 for laxative; Eleotin Cal20 for bone and teeth maintenance; Eleotin V3D for bones, teeth, and health; Eleotin G2000 for cardiovascular health; Eleotin H55 for sedative and tension relief; and Eleotin Zn330 for tissue formation and metabolism. In addition, the company provides Eleotin Bentley to promote healthy glucose levels; and Eleotin LBM for hypertension relief. The company was incorporated in 2010 and is based in Richmond, Canada. Eastwood Bio-Medical Canada Inc. is a subsidiary of Eastwood Bio-Medical Research Inc.

4871 Shell Road, Richmond, BC, Canada, V6X 3Z6

604-247-2100

https://eleotin.ca

Name Title Year Born
Dr. Youngsoo Kim CEO & Director NA
Ms. Yunji Kim Esq. Pres, CFO, Corp. Sec. & Director 1982
Dr. Youngsoo Kim Founder, CEO & Director NA
Ms. Yunji Kim Esq. President, CFO, Corporate Secretary & Director 1982

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

PRL
CAD 30.50
+15.05%
DSV
CAD 11.02
+14.55%
USA
CAD 4.29
+13.19%
NUAG
CAD 7.70
+12.90%
GMIN
CAD 43.79
+12.86%
DRUG
CAD 26.11
-29.58%
HUT
CAD 68.98
-22.41%
UCU
CAD 2.09
-14.34%
VET
CAD 14.87
-14.29%
PHX
CAD 10.96
-13.56%

Equity Sectors*

  • Basic Materials

    +5.46%

  • Communication Services

    +3.38%

  • Consumer Cyclical

    +3.11%

  • Consumer Defensive

    +1.35%

  • Energy

    -4.79%

  • Financial Services

    +2.66%

  • Healthcare

    -0.72%

  • Industrials

    -0.11%

  • Real Estate

    +1.84%

  • Technology

    +1.05%

  • Utilities

    +0.39%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Support

Hi! How can we help you today?

Loading…